loader from loading.io

In the News... Abbott nabs Bigfoot, low-dose aspirin for T2D, can ChatGPT answer diabetes questions? and more!

Diabetes Connections | Type 1 Diabetes

Release Date: 09/08/2023

In the News... Infusion set recall, diabetes & sleep studies, cinnamon clinical trial and more! show art In the News... Infusion set recall, diabetes & sleep studies, cinnamon clinical trial and more!

Diabetes Connections | Type 1 Diabetes

It’s In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: infusion set recall, update on ViaCyte stem cell research, a few new studies look at sleep and diabetes, actual clinical research into cinnamon for type 1 and lots more. Links & transcript below Find out more about Please visit our Sponsors & Partners - they help make the show possible! Edgepark Medical Supplies from extreme temperatures Learn more about Drive The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: ...

info_outline
Ask Us Anything! Moms’ Night Out Providence Panel with Moira McCarthy & Kerri Sparling show art Ask Us Anything! Moms’ Night Out Providence Panel with Moira McCarthy & Kerri Sparling

Diabetes Connections | Type 1 Diabetes

At Moms' Night Out Providence, I was part of an Ask Us Anything panel that included Moira McCarthy and Kerri Sparling. We had a lot of fun on this panel and a lot of fun at MNO period. If you’re wondering what this event is all about, I think this panel will give you a lot of insight. It’s serious, and humorous, I hope helpful, and it’s all peer to peer – we’re not doctors. Moira McCarthy’s daughter, Lauren, was marking 26 years with T1D during this event! Moira is a ski, adventure and travel writer. A JDRF International Volunteer of the Year and author of six books including,...

info_outline
“I’m never going to stop speaking up” Mila Clarke turned her diabetes misdiagnosis into her mission show art “I’m never going to stop speaking up” Mila Clarke turned her diabetes misdiagnosis into her mission

Diabetes Connections | Type 1 Diabetes

This week, Mila Clark became a popular advocate for type 2 diabetes after her diagnosis in 2016 But she was actually one of the many adults misdiagnosed – she actually lives with LADA. One of the biggest changes she experienced was how her health care providers treated her, they were much more supportive when they realized she had LADA – also called type 1.5. Mila is working to reduce the stigma around all types of diabetes. We talk about her advocacy, her Hangry Woman business, the unique patch pump she’s using and a lot more. This podcast is not intended as medical advice. If you have...

info_outline
Know Your Rights! Navigating the Legal Landscape of Diabetes with Lawyer John Griffin show art Know Your Rights! Navigating the Legal Landscape of Diabetes with Lawyer John Griffin

Diabetes Connections | Type 1 Diabetes

Do you know your rights with diabetes? Our guest this week is John Griffin, a trial lawyer with more than 30 years of advocating in and out of the courtroom. He lives with type 2 himself – this is an eye opening and useful conversation.   Griffin served as National Chair of the Board of the American Diabetes Association in 2011, and is the former Chair of the Association’s Legislative and Regulatory Subcommittee.  Also, if you’ve been given a blood glucose meter you probably know how to use it, but do you know how it works? We’ll explain the chemistry going on...

info_outline
In the News... Levemir to be discontinued, Tandem/G7 integration launches, Beta Bionics coverage, and more! show art In the News... Levemir to be discontinued, Tandem/G7 integration launches, Beta Bionics coverage, and more!

Diabetes Connections | Type 1 Diabetes

It’s In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Novo Nordisk will discontinue Levemir by the end of 2024, Tandem begins limited launch of software updates that will include Dexcom's G7, Beta Bionics iLet pump will be covered until some pharmacy plans, and lots more! Links and transcript below Find out more about  Please visit our Sponsors & Partners - they help make the show possible! Edgepark Medical Supplies  from extreme temperatures Learn more about  Drive  The best way...

info_outline
Ask Us Anything! Moms’ Night Out Providence Panel with Moira McCarthy & Kerri Sparling show art Ask Us Anything! Moms’ Night Out Providence Panel with Moira McCarthy & Kerri Sparling

Diabetes Connections | Type 1 Diabetes

At Moms' Night Out Providence, I was part of an Ask Us Anything panel that included Moira McCarthy and Kerri Sparling. We had a lot of fun on this panel and a lot of fun at MNO period. If you’re wondering what this event is all about, I think this panel will give you a lot of insight. It’s serious, and humorous, I hope helpful, and it’s all peer to peer – we’re not doctors. Moira McCarthy’s daughter, Lauren, was marking 26 years with T1D during this event! Moira is a ski, adventure and travel writer. A JDRF International Volunteer of the Year and author of six books including,...

info_outline
“Every patient deserves to fully understand” - Art, medicine, & T1D with Dr. Mike Natter show art “Every patient deserves to fully understand” - Art, medicine, & T1D with Dr. Mike Natter

Diabetes Connections | Type 1 Diabetes

Dr. Mike Natter took a non-traditional path to becoming an endocrinologist, starting out as an art student. But it turns out, the universal language of drawing can help break down barriers Mike lives with type 1 – he was diagnosed at age 9. This is a wide ranging interview, we talk about his diagnosis at age 9, finishing his medical residency in NYC during the height of COVID, what he learned from his test run with the new Beta Bionics iLet pump, and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider....

info_outline
"What do I do now?" - Pro sports photojournalist Keith Crear on life after his type 2 diagnosis

Diabetes Connections | Type 1 Diabetes

This is the first episode of our new show, Diabetes Connections TYPE 2. Here's what we're talking about: What IS an A1C? What you need to know about this all-important number. My guest is a sports photographer and journalist. We’re going to talk about what it takes to do that job and how he was diagnosed with diabetes after a tough run in with the Texas heat.. And hey this is our first episode – we’ll get to know each other a little bit. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. -- A1C information from:...

info_outline
In the News... Weekly basal for T1D, new CGM approved in Europe, T2D caused by pollution? and more... show art In the News... Weekly basal for T1D, new CGM approved in Europe, T2D caused by pollution? and more...

Diabetes Connections | Type 1 Diabetes

It’s In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: a new study looks at pancreatic exocrine-endocrine “crosstalk,” weekly basal for T1D moves forward, a Chinese company gets European approval for its CGM, a look at air pollution as a cause of T2D, lots of info and advocacy for Diabetes Awareness Month including some movies and documentaries. Links and transcript below Find out more about Please visit our Sponsors & Partners - they help make the show possible! Edgepark Medical Supplies from extreme...

info_outline
“That’s the big thing: it’s tiny” - Talking with Tandem Diabetes about the Mobi & more show art “That’s the big thing: it’s tiny” - Talking with Tandem Diabetes about the Mobi & more

Diabetes Connections | Type 1 Diabetes

Tandem’s tiny Mobi pump is FDA approved and set for a limited roll out in the next few weeks. We’ve got a deep dive into its features. Mobi is phone controlled, but it has a button that delivers insulin and more.. This week we're talking with Ben Mar, Tandem’s Director of Product Marketing. We go through all of those features, answer a bunch of your questions about Mobi and about what else is coming up for Tandem. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Mobi:   Find out more about ...

info_outline
 
More Episodes

It’s In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Abbott acquires Bigfoot, a new study looks at low-dose aspirin to prevent type 2, researchers look into whether the AI ChatGPT can answer FAQs about diabetes, Beyond Type Run is back for the NYC Marathon, and more!

Our previous episode with Bigfoot Biomedical: https://diabetes-connections.com/?s=bigfoot

Join us for Moms' Night Out! (use promo code School30 to save)

Please visit our Sponsors & Partners - they help make the show possible!

Take Control with Afrezza 

Omnipod - Simplify Life

Learn about Dexcom 

Learn about Edgepark

Check out VIVI Cap to protect your insulin from extreme temperatures

Learn more about AG1 from Athletic Greens 

Drive research that matters through the T1D Exchange

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

Sign up for our newsletter here

Here's where to find us:

Facebook (Group)

Facebook (Page)

Instagram

Twitter

Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com 

Reach out with questions or comments: [email protected]

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines happening now
XX
In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark
XX
Our top story this week – Abbott scoops up Bigfoot Biomedical. The deal is expected to close later this year – no financial terms yet disclosed. Abbott and Bigfoot have worked together since 2017 on a connected insulin pen system. Bigfoot Unity exclusively works with Abbott's FreeStyle Libre® Long time listeners will recall that Bigfoot was founded in 2015 around serving people with type 1 diabetes with a closed loop pump system that Byran Mazlish had developed for his wife and son. Mazlish was very secretive at first about the algorithm – this was before people were sure the FDA wouldn’t crack down on them – so a journalist nicknamed him Bigfoot. Along the way, the company pivoted to CGM connected SmartPens. I believe Bigfoot was my third interview, back in 2015 – I’ll ink up all of the interviews I’ve done with them in the show notes.
https://diabetes-connections.com/?s=bigfoot
https://www.prnewswire.com/news-releases/abbott-to-acquire-bigfoot-biomedical-furthering-efforts-to-develop-personalized-connected-solutions-for-people-with-diabetes-301918254.html
XX
Low-dose aspirin reduces the risk for type 2 diabetes among older adults and slows the increase in fasting glucose levels over time, new research finds.

The data come from a secondary analysis of ASPREE, a double-blind, placebo-controlled trial of healthy adults aged 65 years or older, showing that 100 mg of aspirin taken daily for about 5 years did not provide a cardiovascular benefit but did significantly raise the risk for bleeding. It’s a big study, more than 16-thousand people.

This new analysis shows that individuals taking aspirin had a 15% lower risk for developing type 2 diabetes and that the medication slowed the rate of increase in fasting plasma glucose, compared with placebo, during follow-up.

However, lead author Sophia Zoungas, MBBS, PhD, head of the School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, says, "Major prescribing guidelines now recommend older adults take daily aspirin only when there is a medical reason to do so, such as after a heart attack… Although these new findings are of interest, they do not change the clinical advice about aspirin use in older people at this time."
https://www.medscape.com/viewarticle/996058
XX
A class-action lawsuit filed against Medtronic (NYSE: MDT)+
alleges that the company’s insulin delivery devices shared patient data with third parties.
The lawsuit — filed by the plaintiff “A.H.” in U.S. District Court in Central California — levels allegations against Medtronic and its MiniMed and InPen devices. It addresses MiniMed’s transmission and disclosure of personally identifiable information and protected health information to Google and other third parties.

Per the lawsuit, the data was transmitted via tracking and authentication technology, including Google Analytics, Crashlytics, Firebase Authentication and related tools. A.H. says these technologies, installed on the website and/or mobile applications, include the InPen iOS and Android applications.

“Information about a person’s health is among the most confidential and sensitive information in society, and its mishandling can have serious consequences, including embarrassment, discrimination, and denial of insurance coverage,” the lawsuit reads.

A Medtronic spokesperson issued the following statement via email:
We have strong processes, technologies, and people in place to safeguard and protect our information and systems, the information of our business partners, and most importantly, the privacy and safety of the patients and healthcare providers that use our products.”
https://www.massdevice.com/lawsuit-patient-data-sharing-medtronic-diabetes/
XX
Interesting new way to look at type 2 – not weight loss or medication, but about reducing how much blood glucose goes up and stays up after eating and drinking. University of Virginia Daniel Cox says this is called Glucose Everyday Matters, or GEM – aims to prevent blood sugar spikes via educated food and drink selection. This is coupled with physical activity to hasten recovery when blood-sugar spikes do occur. So someone might indulge in a piece of fruit or a small, sweet treat, knowing how it will affect them, and then go for an evening stroll to help even out their blood sugar.
Sounds really simple, but in its first study, it helps almost 70-percent of people put their type 2 into remission without weight loss or medication.
The National Institutes of Health has provided $3.5 million for a large-scale clinical trial
Cox himself went from an A1C of 10.3 at the time of diagnoses to reading consistently under 6.0 for the past 13 years on no medication using his approach.
https://newsroom.uvahealth.com/2023/08/31/radical-new-approach-to-managing-type-2-diabetes-receives-3-5-million/

XX
Final preparations are in place to initiate the first clinical site for DIAGNODE-3 in the United States, and additional sites are expected to be initiated over the coming months. Approximately 10-12 clinical sites across the US are planned to be initiated, expanding the DIAGNODE-3 trial in the US and eight European countries to approximately 60 clincal sites in total. DIAGNODE-3 is designed to confirm the efficacy and safety of the antigen-specific immunotherapy Diamyd® in patients aged 12 to 29 years recently diagnosed with type 1 diabetes and carrying the genetic HLA DR3-DQ2 marker.
Approximately 40% of all screened patients carry the genetic HLA DR3-DQ2 haplotype. This proportion aligns well with expectations based on previous Diamyd® clinical trials and published epidemiological research. Supported by published retrospective analyses and prospective clinical trials, the presence of the genetic HLA DR3-DQ2 haplotype determines the likelihood of responding to Diamyd® therapy, and serves as one of the main inclusion criteria in the DIAGNODE-3 trial.

"Patient recruitment is a complex and central element in any trial and it is encouraging to see a significant and continuous uptick in the screening rate and that the observed frequency of the genetically defined responder group enrolled into DIAGNODE-3 confirms our previous observations", says Ulf Hannelius, President & CEO of Diamyd Medical. "This shows the operational and clinical feasibility of our precision medicine approach to Type 1 Diabetes and we look forward to expanding the trial to the United States".
https://finance.yahoo.com/news/registrational-phase-iii-trial-type-142600082.html
XX
A low-carbohydrate diet during pregnancy may have some benefits in gestational diabetes, but overall, low-carbohydrate diets are not associated with any significant differences in outcomes. That was the conclusion of a presentation at the ADA Scientific Sessions. That was back in June but I just learned about it, so I’m passing along to you in case you missed it as well.

During a debate at the American Diabetes Association Scientific Sessions, Amy M. Valent, DO, MCR, associate professor in the division of maternal-fetal medicine in the department of obstetrics and gynecology at Oregon Health & Science University, said identifying

Teri L. Hernandez, PhD, RN, associate dean of research and scholarship in the College of Nursing and professor in the department of medicine and the division of endocrinology, metabolism and diabetes at the University of Colorado Anschutz Medical Campus, agreed that the first line of therapy with gestational diabetes is nutrition. However, Hernandez said, low-carbohydrate diets are not the only approach in gestational diabetes treatment with nutrition.
Currently, dietary advice for treating gestational diabetes is inconsistent, and current professional guidelines have limitations and biases, according to Valent. Different diet strategies include low-carbohydrate, low glycemic index and total energy restriction eating plans, according to Valent. Valent said ACOG guidelines recommended a low-carbohydrate diet for gestational diabetes until the most recently revised edition in January.

Valent reviewed several major landmark studies demonstrating that gestational diabetes treatment can decrease pregnancy complications such as preeclampsia and large for gestational age infants.

“These studies were in the era where treatment of diabetes in pregnancy involved recommending a low-carbohydrate diet,” Valent said. “The concern with lowering carbohydrates is the risk of consuming lower nutrient-dense foods and resulting in the body to produce ketones, which may be associated with negative effects on the developing baby.”

“Pregnancy is dynamic. Nobody’s the same today as they were yesterday. They’re going to be different 1, 2 or 3 weeks from now, and the nutritional demands and the fetal growth and development stage are going to be different,” Valent said. “So, nutritional demands are going to vary.”

Hernandez also added that women and girls tend to be priced out of good nutritional patterns, which is an issue not only in the pregnancy field, but also in the global community. According to Hernandez, it is important to create ways moving forward to identify what nutritional patterns are best that are also affordable for families, especially in lower-income settings.
https://www.healio.com/news/womens-health-ob-gyn/20230905/experts-debate-benefits-of-lowcarb-diets-for-gestational-diabetes

XX
XX
Commercial – Edgepark
XX
Can ChatGPT help answer questions about diabetes?
In a recent study published in the journal PLoS ONE, researchers tested chatGPT, a language model geared for discussion, to investigate whether it could answer frequently asked diabetes questions.

In the present study, researchers evaluated ChatGPT's expertise in diabetes, especially the capacity to answer commonly requested questions related to diabetes in a similar manner as humans.
The 'Frequently Asked Questions' section of the Diabetes Association of Denmark's website, viewed on 10 January 2023, included eight questions. The researchers designed the remaining questions to correlate to particular lines on the 'Knowledge Center for Diabetes website and a report on physical activity and diabetes mellitus type 1.

Across the 10 questions, the proportion of correct responses ranged from 38% to 74%. Participants correctly identified ChatGPT-generated replies 60% of the time, which was over the non-inferiority threshold. Males and females had 64% and 58% chances of accurately recognizing the artificial intelligence-generated response, respectively. Individuals who had past contact with diabetes patients had a 61% chance of precisely answering the questions, compared to 57% for those who had no prior contact with diabetes patients.
In contrast to the initial premise, participants could discern between ChatGPT-generated and human-written replies better than tossing a fair coin.
While ChatGPT demonstrated some potential for accurately answering frequently asked questions, issues around misinformation and the lack of nuanced, personalized advice were evident. As large language models increasingly intersect with healthcare, rigorous studies are essential to evaluate their safety, efficacy, and ethical considerations in patient care, emphasizing the need for robust regulatory frameworks and continuous oversight.

https://www.news-medical.net/news/20230905/Can-ChatGPT-be-a-diabetes-consultant-Study-probes-the-potential-and-pitfalls.aspx
XX
SAN MATEO, Calif., Aug. 24, 2023 /PRNewswire/ -- On November 5, diabetes nonprofit Beyond Type 1 will join more than 550 official charity partners and philanthropists raising awareness and funds while participating in the world's largest marathon, the TCS New York City Marathon. This year, the organization is expanding its 50-person team, Beyond Type Run, to include people living with type 1 or type 2 diabetes, as well as caregivers to those living with diabetes.

"Since 2017, we've featured more than 200 runners on our teams who've exemplified what it means to survive and thrive with diabetes," said Beyond Type 1 CEO Deborah Dugan.

Beyond Type 1 announces the 2023 NYC Marathon team to raise awareness and funds for people living with diabetes

As a part of the Beyond Type Run team, runners will be advocating to raise awareness and funds for Beyond Type 1's portfolio of educational resources, awareness campaigns and peer-to-peer support programs for people impacted by diabetes. This advocacy is elevated through the NYRR Official Charity Partner Program, which offers opportunities for nonprofit organizations to raise funds to support their missions and services.

Dexcom and Tandem Diabetes Care are presenting sponsors of Beyond Type Run for a fourth consecutive year.

The TCS New York City Marathon Official Charity Partner Program has raised more than $440 million for more than 1,000 nonprofit organizations since its establishment in 2006.
https://www.prnewswire.com/news-releases/team-of-50-individuals-impacted-by-diabetes-prepare-for-the-2023-tcs-new-york-city-marathon-301909163.html
XX
MNO update
On the podcast next week.. tandem diabetes celebrity panel from friends for life – Hollywood, the NFL and NASCAR. Last week’s episode was Benny off to college

That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
----